SCHEMBL21883612

SCHEMBL21883612

CCCCCc1nccc(/C=N/OC)c1N

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ TLR4 O00206 3/20 0.32
▸ DHFR P00374 1/20 0.32
▸ TLR8 Q9NR97 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ ADRA1D P25100 1/20 0.30
▸ ADRA1A P35348 1/20 0.30
▸ ADRA1B P35368 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19779244 0.77 DHFR (0.37) TLR7TDP1L3MBTL1DHFRTLR8
SCHEMBL22096855 0.73 KDR (0.32) ADRA1DADRA1AADRA1B
SCHEMBL20621302 0.71 ADRA2A (0.33) ADRA1DADRA1AADRA1B
SCHEMBL21883574 0.70 NOS2 (0.46) TLR7TDP1L3MBTL1DHFRTLR8
SCHEMBL15923846 0.68 TSHR (0.38) TDP1L3MBTL1DHFRTLR8KDM4E
SCHEMBL8713669 0.66 NOS2 (0.49) TLR7TDP1L3MBTL1TLR8KDM4E
SCHEMBL19880572 0.66 KDM4E (0.41) TDP1L3MBTL1DHFRKDM4EMEN1
SCHEMBL17335193 0.65 CYP2C9 (0.38) KDM4EMEN1USP2ALDH1A1RAB9A
SCHEMBL1074604 0.64 TDP1 (0.47) TLR7TDP1L3MBTL1TLR8KDM4E
SCHEMBL28009761 0.64 NOS2 (0.42) TLR7TDP1L3MBTL1DHFRTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 TLR7 2376/4885TDP1 2824/4885L3MBTL1 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback